High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol
Gunnar Cario,
Peter Rhein,
Rita Mitlöhner,
Martin Zimmermann,
Obul R. Bandapalli,
Renja Romey,
Anja Moericke,
Wolf-Dieter Ludwig,
Richard Ratei,
Martina U. Muckenthaler,
Andreas E. Kulozik,
Martin Schrappe,
Martin Stanulla,
Leonid Karawajew
Affiliations
Gunnar Cario
Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel
Peter Rhein
Department of Pediatric Oncology/Hematology, Charité – Universitätsmedizin Berlin
Rita Mitlöhner
Department of Pediatric Oncology/Hematology, Charité – Universitätsmedizin Berlin
Martin Zimmermann
Department of Pediatric Hematology/Oncology, Medical School Hannover
Obul R. Bandapalli
Department of Pediatric Oncology, Hematology and Immunology, Children’s Hospital, University of Heidelberg
Renja Romey
Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel
Anja Moericke
Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel
Wolf-Dieter Ludwig
Department of Hematology, Oncology and Tumor Immunology, HELIOS-Clinic Berlin-Buch, Berlin, Germany
Richard Ratei
Department of Hematology, Oncology and Tumor Immunology, HELIOS-Clinic Berlin-Buch, Berlin, Germany
Martina U. Muckenthaler
Department of Pediatric Oncology, Hematology and Immunology, Children’s Hospital, University of Heidelberg
Andreas E. Kulozik
Department of Pediatric Oncology, Hematology and Immunology, Children’s Hospital, University of Heidelberg
Martin Schrappe
Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel
Martin Stanulla
Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel;Department of Pediatric Hematology/Oncology, Medical School Hannover
Leonid Karawajew
Department of Pediatric Oncology/Hematology, Charité – Universitätsmedizin Berlin
Further improvement of outcome in childhood acute lymphoblastic leukemia could be achieved by identifying additional high-risk patients who may benefit from intensified treatment. We earlier identified PTPRC (CD45) gene expression as a potential new stratification marker and now analyzed the prognostic relevance of CD45 protein expression. CD45 was measured by flow cytometry in 1065 patients treated according to the ALL-BFM-2000 protocol. The 75th percentile was used as cut-off to distinguish a CD45-high from a CD45-low group. As mean CD45 expression was significantly higher in T-cell acute lymphoblastic leukemia than in B-cell-precursor acute lymphoblastic leukemia (P
